Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice

NCT06907082 · clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
106
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia